Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime–adenovirus boost

SH Park, SH Yang, CG Lee, JW Youn, J Chang… - Vaccine, 2003 - Elsevier
SH Park, SH Yang, CG Lee, JW Youn, J Chang, YC Sung
Vaccine, 2003Elsevier
Hepatitis C virus (HCV) is an important causative agent of liver disease, but currently there is
no available prophylactic vaccine against HCV infection. Here, we investigated the HCV E2-
and core-specific T-cell responses induced by DNA (D) and/or recombinant adenovirus (A)
vaccines. In single (D versus A) or double immunizations (DD versus AA), the recombinant
adenovirus vaccines induced higher levels of IFN-γ secreting T-cell response and cytotoxic
T lymphocytes (CTL) response than the DNA vaccines. However, a heterologous (DA) …
Hepatitis C virus (HCV) is an important causative agent of liver disease, but currently there is no available prophylactic vaccine against HCV infection. Here, we investigated the HCV E2- and core-specific T-cell responses induced by DNA (D) and/or recombinant adenovirus (A) vaccines. In single (D versus A) or double immunizations (D-D versus A-A), the recombinant adenovirus vaccines induced higher levels of IFN-γ secreting T-cell response and cytotoxic T lymphocytes (CTL) response than the DNA vaccines. However, a heterologous (D-A) regimen elicited the highest level of T helper 1 (Th1) CD4+ T-cell responses. Furthermore, three E2-specific CTL epitopes were mapped using a peptide pool spanning the E2 protein sequence (a.a. 384–713) in BALB/c mice, and one of these (E2 405–414: SGPSQKIQLV) was shown to be immunodominant. Interestingly, no significant differences were found in the repertoire of E2-specific T-cell responses or in the immunodominance hierarchy of the three epitopes induced by D-D, D-A, A-A, and A-D, indicating that the breadth and hierarchy of T-cell responses is independent of these different vaccination regimens. In conclusion, the heterologous DNA prime–recombinant adenovirus boost regimen described offers an efficient promising strategy for the development of an effective T-cell-based HCV vaccine.
Elsevier